Medivation’s Acquisition for $14 Billion by Pfizer Near Final Stage: Reports
As Pfizer Inc seeks to boost its oncology portfolio, it has reached a position of advanced talks for the acquisition of the U.S. cancer drug company, Medivation Inc, for a value that is believed to be close to $14 billion, the media reported citing sources with knowledge of the matter. One of the sources was…








